Geron (NASDAQ:GERN – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports.

Geron stock opened at $1.64 on Wednesday. Geron has a 1-year low of $1.46 and a 1-year high of $5.34. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -5.13 and ...

When he emerged from the Alaskan interior, the first news he heard was that William McKinley, the former governor of Ohio, had received the Republican nomination for president. And so, in the kind ...

President William McKinley is having his biggest moment since 1928, when his face was printed on the $500 bill. For the last few decades, only a smattering of quirky historians and cult devotees have ...

SAN DIEGO, March 14, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Geron Corporation (NASDAQ ...

Reciprocal trade policy as envisioned by President William McKinley, whom Mr. Trump often cites as his role model, recognized that by the dawn of the 20th century America had emerged as an ...

Photo: Jim Watson/AFP/Getty Images/Christopher Katsarov Luna/Bloomberg News/Yuri Gripas/Zuma Press Donald Trump mentioned two presidents in his Second Inaugural Address: William McKinley and ...

Drew Sidora entangles Dennis McKinley in ‘The Real Housewives of Atlanta’ season 16 Dennis McKinley and Porsha Williams on season 11 of ‘The Real Housewives of Atlanta’ in 2018 | Annette ...

Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

A defamation lawsuit stemming from a 2021 incident involving the discipline of a McKinley High School football player has been settled without a trial. Former head football coach Marcus Wattley ...

On Wednesday, H.C. Wainwright maintained a Neutral rating on Geron Corporation (NASDAQ:GERN) following the recent approval of its drug Rytelo by the European Commission. According to InvestingPro ...

resulting in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting. The ...